FSD Pharma – Financial Treason & Crime

FSD Pharma: A Rollup With Scattered, Uneconomical Cannabis Investments, 50-70% Downside

WHITE DIAMOND, 25 January 2019

FSD Pharma’s founder, Thomas Fairfull, and director, Anthony Durkacz, have a history of value destruction. Durkacz had an average loss of 92% over 11 stocks in which he had involvement. The company spent $8 million on listing fees, which is a head-scratcher, as it is multiple times larger than what comps spend. Durkacz has received an astounding sum of over C$28.7 million total current value in cash and warrants for being both a director and broker for FSD. FSD Pharma routinely announces investing in other small cannabis companies, but so far has shown little follow-through. We have a price target on FSD of C$0.09 per share, which was its pre-RTO financing price less than a year ago.
Continue reading “Article: FSD Pharma: A Rollup With Scattered, Uneconomical Cannabis Investments, 50-70% Downside”

It’s happening again: FSD Pharma (HUGE.C) is an insider loaded, overvalued, restrictive mess

CHRIS PARRY, 31 May 2018

What the hell is in the vodka on Howe Street that all of a sudden every new weed deal is coming out tied in knots that enrich the core crew at the expense of everyone else? We’ve spent three days shining a light on MedMen’s (MMEN.C) terrible go-public structure, which enriches execs at the expense of the company and shareholders, and showers them in bonuses every month, a situation that has led to around $400 million in market cap disintegrating over the last few days. Sure, In Vancouver we’re used to deals where insiders are loaded with literal penny (or ha’penny) stock before they even announce what’s going into their shell, and we know that’s one of the costs of doing business on the Venture Exchange – that those early guys will blow their cheap paper out and the company will face pressure as a result.
Continue reading “Article: It’s happening again: FSD Pharma (HUGE.C) is an insider loaded, overvalued, restrictive mess”